BiotechTube

Osmotic drugs

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stroke

Conditions

Stroke

Trial Timeline

Jul 1, 2023 → Jan 1, 2027

NCT ID
NCT05914272

About Osmotic drugs

Osmotic drugs is a pre-clinical stage product being developed by Sinopharm for Stroke. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05914272. Target conditions include Stroke.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05914272Pre-clinicalRecruiting

Competing Products

20 competing products in Stroke

See all competitors
ProductCompanyStageHype Score
SPT-07A injectionSinopharmPhase 3
76
Aspirin, ClopidogrelYuhanPre-clinical
23
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
41
SUN13837 + placeboDaiichi SankyoPhase 2
52
DS-1040b + AspirinDaiichi SankyoPhase 1
33
piclozotan low dose + placebo + piclozotan high doseDaiichi SankyoPhase 2
52
DS1040b + PlaceboDaiichi SankyoPre-clinical
23
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
52
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
77
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
52
ASP2246Astellas PharmaPhase 1/2
41
Neu2000KWL + Neu2000KWL + Neu2000KWL + PlacebosSun PharmaceuticalPhase 2
52
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
52
Redasemtide + PlaceboShionogiPhase 2
52
StatinShionogiApproved
85
AlteplaseKyowa KirinApproved
85
ONO-2506 + ONO-2506 + ONO-2506Ono PharmaceuticalPhase 2/3
65
AbciximabEli LillyPhase 3
77
AbciximabEli LillyPhase 3
77
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
52

Other Products from Sinopharm

SPT-07A injectionPhase 3
76
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboPhase 2
51
Unfractionated heparinPre-clinical
22